French medical device company inHeart has raised more than €10 million in order to speed up the creation and launch of new therapeutic, predictive, and screening cardiac solutions. The round was led by Vesalius Biocapital IV and co-led by Elaia Partners.NACO, Sagana, Sofia Angel Ventures, CWR funds, and Webit Investment Network took part as well.
- inHEART was founded in 2017 by Jean-Marc Peyrat. To improve the care of patients with heart disease, it is providing the first digital twin of the heart powered by AI. The present treatment option offered by inHEART addresses the weaknesses of traditional cardiac ablations.
- The inHEART solution uses AI-driven cardiac CT or MR image segmentation to produce detailed, interactive 3D heart models. With the use of these 3D cardiac models, doctors can better tailor their treatment plans to the particular cardiac anatomy of each patient, easing pre-procedural planning that leads to quicker ablation treatments and better patient results.
- Through a direct sales force approach, inHEART is currently commercially available in the US and EU.
“It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions,” said Todor Jeliaskov, chairman and CEO of inHEART.
- The round’s leading investor was life-science venture capital Vesalius Biocapital IV, launched in 2023. It focuses on investments in healthtech and biopharma, having two startups in its portfolio at this moment.
“inHEART's AI-driven solutions exemplify the future of cardiac care, offering personalized therapy options and predictive models that can enhance clinical outcomes and streamline treatment processes. We're excited to contribute to inHEART's journey as they revolutionize cardiac care and address global healthcare needs with cutting-edge technology and innovation,” shared Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV.
- The funding is planned to be used to further the development of predictive cardiac models for heart failure, sudden cardiac death, and cardio-embolic stroke, as well as to push the commercial expansion of their cardiac ablation therapy solution.
